NextCure Enters Licensing Agreement with Simcere Zaiming

The latest announcement is out from NextCure ( (NXTC) ).

On June 13, 2025, NextCure, Inc. entered into a licensing agreement with Hainan Simcere Zaiming Pharmaceutical Co., Ltd., granting NextCure exclusive rights outside of Greater China to develop, manufacture, and commercialize the antibody-drug conjugate SIM0505. This strategic partnership aims to advance SIM0505, currently in Phase 1 clinical trials in China, with U.S. trials expected to start in the third quarter of 2025. The agreement includes milestone payments and royalties, reflecting the potential impact on NextCure’s operations and market positioning. Additionally, NextCure announced a private placement agreement with Simcere Zaiming, Inc., involving the sale of common stock to support its operations.

The most recent analyst rating on (NXTC) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on NextCure stock, see the NXTC Stock Forecast page.

Spark’s Take on NXTC Stock

According to Spark, TipRanks’ AI Analyst, NXTC is a Underperform.

NextCure’s overall stock score reflects significant financial challenges, including a lack of revenue and ongoing cash burn typical of early-stage biotech firms. The technical analysis suggests a bearish trend with potential volatility, while valuation metrics are unfavorable due to negative earnings. Despite a positive corporate event related to clinical trials, the company must urgently address its financial sustainability through partnerships or additional funding to enhance its long-term prospects.

To see Spark’s full report on NXTC stock, click here.

More about NextCure

NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer patients who do not respond to current treatments. The company leverages its expertise in biological pathways, biomarkers, and cell interactions to advance therapies, including antibody-drug conjugates, aimed at treating cancer through differentiated mechanisms of action.

Average Trading Volume: 192,717

Technical Sentiment Signal: Sell

Current Market Cap: $19.1M

See more insights into NXTC stock on TipRanks’ Stock Analysis page.